Apollo Hospitals: Q2FY23 Result
15-11-2022

Market Cap Rs. 65,421 cr

CMP Rs. 4,550 |PE 78x TTM

Results

INR Cr.

Y-o-Y Growth

Comments

Revenue

4,251

11.4%

Hospital revenue grew 4.4%, Pharmacy business grew by 12.8%

EBITDA

565

-8.1%

EBITDA margin came in at 13.3% (-320bps YoY ) primarily due to higher operating costs related to 24x7

Click here for 10 year X-ray

 

Key Highlights:

  • Healthcare services in-patient volumes were up 19% YoY and 13% QoQ. Revenue growth ex-Covid vaccination was 12%. Mature hospitals grew 15% and new hospitals grew 4% YoY.
  • Occupancy across the group was 68% vs 65% in Q2FY22. Occupancy in mature hospitals was 70% and in new hospitals was 64%.
  • ARPOB declined 3.2% sequentially to Rs. 50,353. ALOS was 3.44 days.
  • Diagnostics & Retail Health posted combined revenues of Rs. 318cr (+12% YoY). Diagnostics crossed the Rs. 100cr revenue threshold.
  • Private labels contributed to 11% of the revenue in the pharmacy distribution business. 241 new stores were opened, total store count now at 5,004.

 

Management Outlook:

  • Cost and productivity initiatives can improve margins by 100-150bps over the next 18 months.
  • It has headroom for growing occupancy to 82%-83%, but the target for this year is 70% at the group level.
  • 2,000 beds to be added over the next 3-4 years at a cost of ~Rs. 3,000 cr. Apart from this, recurring (maintenance) capex is Rs. 350 cr.
  • It expects the diagnostics business to cross revenues of Rs. 500 cr in FY24 and Rs. 1,000 cr over the next 3 years.
  • Commercialization of the Gurgaon facility to take 18 months.
  • Same centre growth for diagnostic business to be in the range of 15%-20% (entirely volume led). The company is holding prices, no further increase or decrease in prices is expected.
  • Other online pharmacies give ~20%-22% discount; Apollo is at 17.5%-18%. Possibility to maintain the same levels or even lower the discounts 150ps.
  • 800 brick and mortar pharmacies to be added this fiscal. Target is 6,500 stores by FY25.
  • Share of private labels in pharmacy distribution to increase to 12%-13% over the next 12 months.

 

Disclosure: MoneyWorks4me's employees may have exposure in the securities mentioned in the above report. For detailed disclosure click here.

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×